B. Riley Cuts Joint (NASDAQ:JYNT) Price Target to $18.00

Key Points

• B. Riley has reduced its price target for Joint (NASDAQ:JYNT) from $20.00 to $18.00, while still maintaining a "buy" rating, suggesting a potential upside of 67.91% from the current stock price.
• Joint's stock opened at $10.72 and has a market capitalization of $164.02 million, with a price-to-earnings ratio of -19.40 and a recent buyback plan authorized for up to $5 million in shares.
• Significant institutional interest has been noted, with 76.88% of the company's stock owned by institutional investors, highlighting a notable increase in holdings from firms like Nisa Investment Advisors and Wells Fargo.

Joint (NASDAQ:JYNT - Get Free Report) had its price objective reduced by equities researchers at B. Riley from $20.00 to $18.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the stock. B. Riley's price objective points to a potential upside of 60.03% from the company's previous close. B. Riley also issued estimates for Joint's Q4 2025 earnings at $0.16 EPS, FY2026 earnings at $0.52 EPS and FY2027 earnings at $0.68 EPS.

Separately, Lake Street Capital reduced their price objective on Joint from $20.00 to $16.00 and set a "buy" rating on the stock in a report on Friday, May 9th.

Joint Price Performance

Shares of JYNT traded up $0.45 on Friday, hitting $11.25. The company's stock had a trading volume of 30,647 shares, compared to its average volume of 58,541. The company has a market capitalization of $172.09 million, a PE ratio of -34.05 and a beta of 1.53. Joint has a fifty-two week low of $9.58 and a fifty-two week high of $13.47. The company has a 50 day moving average price of $11.48 and a 200 day moving average price of $11.10.

Joint (NASDAQ:JYNT - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.01. Joint had a positive return on equity of 0.67% and a negative net margin of 7.02%. The firm had revenue of $13.27 million for the quarter, compared to the consensus estimate of $13.32 million. On average, equities analysts forecast that Joint will post 0.11 EPS for the current year.

Joint announced that its Board of Directors has approved a stock repurchase plan on Thursday, June 5th that allows the company to buyback $5.00 million in shares. This buyback authorization allows the company to reacquire up to 2.7% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board believes its stock is undervalued.

Institutional Trading of Joint

Several institutional investors and hedge funds have recently made changes to their positions in JYNT. Geode Capital Management LLC raised its position in shares of Joint by 0.5% during the 4th quarter. Geode Capital Management LLC now owns 293,133 shares of the company's stock valued at $3,116,000 after acquiring an additional 1,552 shares during the last quarter. Wells Fargo & Company MN raised its position in shares of Joint by 51.7% during the 4th quarter. Wells Fargo & Company MN now owns 5,088 shares of the company's stock valued at $54,000 after acquiring an additional 1,735 shares during the last quarter. Barclays PLC raised its position in shares of Joint by 6.9% during the 4th quarter. Barclays PLC now owns 27,380 shares of the company's stock valued at $291,000 after acquiring an additional 1,771 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of Joint by 4.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 216,254 shares of the company's stock valued at $2,299,000 after buying an additional 10,074 shares in the last quarter. Finally, Topline Capital Management LLC bought a new stake in shares of Joint in the 4th quarter valued at $3,458,000. Institutional investors own 76.88% of the company's stock.

Joint Company Profile

The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.